The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Allakos Inc COM 01671P100 23,959 458,366 SH   SOLE   458,366 0 0
Aravive Inc COM 03890D108 1,558 442,733 SH   SOLE   442,733 0 0
Catabasis Pharmaceuticals Inc COM 14875P206 1,311 300,000 SH   SOLE   300,000 0 0
Edge Therapeutics Inc COM 279870109 59 183,332 SH   SOLE   183,332 0 0
Evelo Biosciences Inc COM 299734103 2,960 227,529 SH   SOLE   227,529 0 0
Intercept Pharmaceuticals Inc COM 45845P108 23,623 234,375 SH   SOLE   234,375 0 0
KalVista Pharmaceuticals Inc COM 483497103 2,963 150,000 SH   SOLE   150,000 0 0
Liquidia Technologies Inc COM 53635D202 8,197 378,420 SH   SOLE   378,420 0 0
Millendo Therapeutics Inc COM 60040X103 359 45,101 SH   SOLE   45,101 0 0
Miragen Therapeutics Inc COM 60463E103 2,755 909,090 SH   SOLE   909,090 0 0
Odonate Therapeutics Inc COM 676079106 8,390 595,850 SH   SOLE   595,850 0 0
Principia Biopharma Inc COM 74257L108 10,504 383,480 SH   SOLE   383,480 0 0
Surface Oncology Inc COM 86877M209 332 78,300 SH   SOLE   78,300 0 0
Sutro BioPharma Inc COM 869367102 10,153 1,125,576 SH   SOLE   1,125,579 0 0
Syros Pharmaceuticals Inc COM 87184Q107 5,904 1,059,938 SH   SOLE   1,059,938 0 0
Trillium Therapeutics Inc COM 89620X506 122 71,619 SH   SOLE   71,619 0 0
Urovant Sciences Ltd COM G9381B108 1,038 157,480 SH   SOLE   157,480 0 0